LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning.
- TRADE NAME: Odefsey (Gilead)
- INDICATIONS: HIV-1 infection
- CLASS: Hepatitis B virus necleoside analog reverse transcriptase inhibitor (tenofovir alafenamide), Non-nucleoside reverse transcriptase inhibitor (rilpivirine), Nucleoside analog reverse transcriptase inhibitor (emtricitabine)
- HALF-LIFE: 10 hours (emtricitabine); 50 hours (rilpivirine); <1 hour (tenofovir alafenamide)
- FDA APPROVAL DATE: 03/01/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Dexamethasone, Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Oxcarbazepine, Pantoprazole, Phenobarbital, Phenytoin, Rabeprazole, Rifampin, Rifapentine, St John's Wort - PREGNANCY: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
